CoreCap Advisors’s Editas Medicine EDIT Stock Holding History

CoreCap Advisors’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$49	Hold	15	–	–	﹤0.01%	3118
2026 Q1	$37	Hold	15	–	–	﹤0.01%	2891
2025 Q4	$31	Hold	15	–	–	﹤0.01%	2920
2025 Q3	$52	Sell	15 -100	-87%	-$279	﹤0.01%	2753
2025 Q2	$253	Hold	115	–	–	﹤0.01%	2596
2025 Q1	$133	Hold	115	–	–	﹤0.01%	3036
2024 Q4	$146	Sell	115 -215	-65%	-$548	﹤0.01%	2750
2024 Q3	$1.13K	Sell	330 -170	-34%	-$740	﹤0.01%	2253
2024 Q2	$2.33K	Buy	+500	New	+$2.82K	﹤0.01%	1296
2022 Q4	$648	Buy	+73	New	+$801	﹤0.01%	2129
2022 Q3	–	Sell	-73	Closed	-$1K	–	948
2022 Q2	$1K	Buy	+73	New	+$978	﹤0.01%	1974
2022 Q1	–	Sell	-73	Closed	-$2K	–	957
2021 Q4	$2K	Buy	+73	New	+$2.51K	﹤0.01%	1942

Other funds holding EDIT

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

CoreCap Advisors's EDIT Position: Q2 2026 in Review

CoreCap Advisors held its Editas Medicine (EDIT) position steady in Q2 2026 at 15 shares worth $49. The position accounts for ﹤0.01% of the portfolio, ranked #3118.

CoreCap Advisors first reported a position in EDIT in Q4 2021 and has held it in 12 quarters since. The position peaked at $2.33K in Q2 2024. 214 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

CoreCap Advisors held 15 shares of Editas Medicine worth $49 as of Q2 2026.
CoreCap Advisors left its Editas Medicine share count unchanged in Q2 2026.
Editas Medicine made up ﹤0.01% of CoreCap Advisors's portfolio in Q2 2026, its #3118 holding.
CoreCap Advisors first reported a position in Editas Medicine in Q4 2021 and has held it in 12 quarters since.
CoreCap Advisors's Editas Medicine position peaked at $2.33K in Q2 2024.
214 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on CoreCap Advisors's 13F filing for Q2 2026, filed 6 Jul 2026.